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Background: Acute stroke treatment is a time-critical process in which every minute
counts. Laboratory biomarkers are needed to aid clinical decisions in the diagnosis.
Although imaging is critical for this process, these biomarkers may provide additional
information to distinguish actual stroke from its mimics and monitor patient condition and
the effect of potential neuroprotective strategies. For such biomarkers to be effectively
scalable to public health in any economic setting, these must be cost-effective and
non-invasive. We hypothesized that blood-based combinations (panels) of proteins might
be the key to this approach and explored this possibility through a systematic review.
Methods: We followed the PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analysis) guidelines for systematic review. Initially, the broader search for
biomarkers for early stroke diagnosis yielded 704 hits, and five were added manually.
We then narrowed the search to combinations (panels) of the protein markers obtained
from the blood.
Results: Twelve articles dealing with blood-based panels of protein biomarkers for
stroke were included in the systematic review. We observed that NR2 peptide (antibody
against the NR2 fragment) and glial fibrillary acidic protein (GFAP) are brain-specific
markers related to stroke. Von Willebrand factor (vWF), matrix metalloproteinase 9
(MMP-9), and S100β have been widely used as biomarkers, whereas others such as
the ischemia-modified albumin (IMA) index, antithrombin III (AT-III), and fibrinogen have
not been evaluated in combination. We herein propose the following new combination
of biomarkers for future validation: panel 1 (NR2 + GFAP + MMP-9 + vWF + S100β),
panel 2 (NR2+ GFAP+MMP-9+ vWF+ IMA index), and panel 3 (NR2+ GFAP+ AT-III
+ fibrinogen).
Conclusions: More research is needed to validate, identify, and introduce these panels
of biomarkers into medical practice for stroke recurrence and diagnosis in a scalable
manner. The evidence indicates that the most promising approach is to combine different
blood-based proteins to provide diagnostic precision for health interventions. Through
our systematic review, we suggest three novel biomarker panels based on the results in
the literature and an interpretation based on stroke pathophysiology.
Keywords: stroke, diagnosis, biomarker panels, serum biomarkers, neuroprotection
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BACKGROUND
Stroke remains to be the second leading cause of death
worldwide, with a yearly death toll of 5.5 million (1, 2).
Furthermore, approximately 116.4 million people are reportedly
disabled because of stroke, resulting in stroke being one
of the most important causes of disability in older people
(3). Consequently, cerebrovascular diseases have substantial
economic impact and significant social consequences. This
impact is exacerbated in lower- and middle-income countries.
Evidence suggests that this situation is due to insufficient and
non-optimal strategies for the prevention of cerebrovascular
diseases and due to reduced availability of equipment for the
diagnosis and treatment in medical centers (4).
Many of the shortcomings in managing stroke and related
diseases are due to the heterogeneity of these pathologies. The
main subtypes of stroke are ischemic and hemorrhagic stroke.
Ischemic stroke is characterized by a lack of blood supply to
a part of the brain, whereas hemorrhagic stroke refers to a
cerebral bleed due to a blood vessel’s rupture (5). Ischemic
stroke in turn comprises different subtypes such as transient
ischemic attack (TIA), which is transitory and reversible in
nature. We followed the classification system: Trial of Org 10172
in Acute Stroke Treatment (TOAST) developed by Adams et al.
(6), and we further distinguished large-artery atherosclerosis,
cardioembolic (CE), lacunar, undetermined etiology, and other
determined etiology.
Several studies have shown that subjects with TIA have a
much higher probability of future strokes than the general
population (7–9). In fact, the recurrence estimated by the
Oxfordshire Community Stroke Project varies between 8 and
12% at 7 days, 11 and 15% at 1 month, and 15 and 19%
at 3 months (8). Notably, recurrent events tend to become
more disabling or fatal than the first stroke or TIA (9).
Therefore, the first occurrence of TIA constitutes a warning
signal for future stroke, offering a unique opportunity for early
interventions and stroke prevention, including neuroprotective
strategies (Figure 1). As one of the reviewers have highlighted,
“acute stroke treatment is a time-critical process where every
minute counts.”
Unfortunately, physicians may neglect these warning signals
for recurrent future cerebrovascular events. In addition,
misdiagnosis and untimely discharge are also relatively frequent
(10). A TIA is a predictive factor for recurrence (11), and
therefore, there is a strong need to determine the predictors
of recurrence after the first TIA event. Early identification of
patients at a higher risk for stroke recurrence may offer critical
insights for urgent management and recurrence prevention.
Abbreviations: AIS, acute ischemic stroke; IS, ischemic stroke; ICH, intracerebral
hemorrhage; TIA, transient ischemic attack; SAH, subarachnoid hemorrhage;
VCAM, vascular cell adhesion molecule; vWF, von Willebrand factor; BNGF,
B-type neurotrophic growth factor; CRP, C-reactive protein; sRAGE, soluble
receptor for advanced glycation end products; MMP-9, matrix metalloproteinase
9; BNP, brain natriuretic peptide; TIMP-4, metalloproteinase inhibitor-4; UCH-
L1, ubiquitin C-terminal hydrolase 1; CE, cardioembolic stroke subtype; LVD,
large-vessel disease stroke subtype; SVD, small-vessel disease; UDE, undetermined
etiology; ELISAs, enzyme-linked immunosorbent assay.
FIGURE 1 | Changing risks of stroke recurrence in a population. Schematic
diagram of the risk of stroke recurrence in the general population. There are
mainly two groups: those with low risk (without any disease apparently) and
those with high risk (people with prior cardiovascular diseases, diabetes, and
hypertension). The probability of experiencing a transient ischemic attack (TIA)
was higher in the high-risk group than that in the low-risk group. In addition, a
TIA event increases the probability of recurrent stroke. Recognition of this risk
structure provides a unique opportunity for early health interventions and
stroke prevention.
Stroke onset in patients requires additional factors that, ideally,
are differentiation from stroke mimics, classification of stroke
subtypes, and monitoring patient progression.
Early identification of such aspects is the goal of precision
medicine for all diseases. This approach leverages disease
progression models whose stages are identifiable using
biomarkers (12, 13). In this framework, a biomarker is
a parameter that may indicate the likelihood of disease
progression or clinical events in subjects with a specific medical
condition (14).
Regrettably, stroke remains to be a condition without well-
established biomarkers, which, alone or in combination, are
precise enough for a useful prediction. This situation seems
contradictory, as an increasing number of biomarker candidates
are continuously being proposed (15). However, selecting specific
stroke biomarkers remains challenging for several reasons.
Stroke, as mentioned before, is a heterogeneous disease
that involves diverse mechanisms that affect the specificity
and sensitivity of potential biomarkers (16, 17). These
mechanisms include disruption of the blood–brain barrier,
thrombus formation, neuronal death, excitotoxicity,
mitochondrial dysfunction, and immune system activation
[(18); Figure 2]. Biomarkers may be sensitive to different facets
of pathophysiology and may change over time.
Stroke diagnosis depends crucially on neuroimaging;
computed tomography (CT) remains an essential component of
stroke management, although it is not always available. Some
areas of stroke management have been neglected, such as using
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FIGURE 2 | Stroke pathophysiology. The clot formation process starts with disrupting the blood–brain barrier due to a rupture of the endothelial cell layer, exposing the
blood vessel’s inner collagen layer. Collagen exposure is recognized by circulating platelets in the bloodstream, which initiates the process of aggregation. Fibrinogen
is released from the liver to the bloodstream and is cleaved by thrombin at the damaged site, resulting in fibrin formation. Fibrin is one of the main constituents of
blood clots, providing remarkable biochemical and mechanical stability. The blood clot is also composed of neutrophils and leukocytes that arrive at the injured site
and form a solid structure that obstructs or reduces blood flow. The reduction in blood flow leads to a decrease in oxygen and glucose levels. These conditions favor a
shift in the neuron’s metabolic conditions, mitochondrial dysfunction, excitotoxicity, ion imbalance, and neuronal death. Figure was drawn using Biorender.com.
biomarkers to predict stroke after TIA, and only a few studies
have evaluated the risk of recurrent events in TIA subjects.
Consequently, there is no clinical setting in which the use of a
biomarker might help an individual patient. Acute stroke therapy
is guided by the severity of the clinical symptoms and imaging.
A preliminary study of the literature also indicated that single
biomarkers achieved relatively low diagnostic accuracy.
To summarize, the use of biomarkers for stroke diagnosis
is a challenging issue because, unlike for myocardial infarction,
cerebral imaging remains the gold standard for stroke diagnosis.
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Therefore, expectations regarding the use of biomarkers in stroke
patients should be realistic. We suggest that the primary use of
biomarkers in stroke patients is to provide additional laboratory
information to effectively distinguish between actual stroke and
its mimics and to monitor patient condition and the effect of
potential neuroprotective strategies.
To highlight promising directions, we present a systematic
review of the literature on stroke biomarkers for the purposes
mentioned above. This review comprises the following:
1. A preliminary review of the literature indicated that
combinations of stroke biomarkers (“panels”) showed
increased diagnostic accuracy. Thus, we focused on panels of
biomarkers instead of isolated determinations.
2. We limited our attention to only those studies that
reported the area under the receiver operating characteristic
(ROC) curve (AUC). This choice allowed for quantitative
comparisons of accuracy.
3. Because of the paucity of studies reported in the literature
on subtype classification of stroke through biomarker
combinations, we narrowed our search to the small-vessel-
disease subtype of stroke.
4. We also focused our review on blood-based biomarkers as
they seem to offer several advantages in terms of cost and ease
of scalability (12).
As a consequence of our review, we propose new combinations
that highlight the pathophysiological processes related to the
selected biomarkers.
Overall, we adopted this scope for our review because of
the geographical distribution of stroke. The highest incidence
of stroke has been reported in high-income countries. Better
reporting and shifting demographics place the onus on the
developing world, with an increase of 91.4 million disability-
adjusted life-years and 4.85 million deaths in proportion to all
global causes (4, 19). Thus, technologies that are deployable
without advanced analytical or imaging technologies need to
be explored in more detail. Blood-based biomarker panels may




We developed a search strategy with assistance from a
research committee formed by neurologists, molecular biologists,
mathematicians, and bioinformaticians. The search strategy was
established using a combination of standardized MeSH (Medical
Subject Headings) terms and keywords, including but not limited
to (-cerebrovascular disorder or brain vascular disorders or
vascular diseases, intracranial or intracranial vascular disease
or cerebrovascular occlusion or cerebrovascular accident or
intracranial embolism, and thrombosis or cerebrovascular
insufficiencies) AND (- ischemia or Stroke or infarction or
brain infarction or hypoxia-ischemia or brain ischemia or
ischemic attack) AND (-intracerebral hemorrhage, cerebral
hemorrhage, or intracranial hemorrhage) AND (- biological
marker or biomarker or biologic marker or marker, biological,
or biomarker panel) AND (- blood plasma sample, serum
plasma sample, cerebrospinal fluid, blood proteins, plasma,
blood, marker, serum, or serum marker or laboratory markers)
AND (- diagnoses or diagnostic or examinations). The search
encompassed studies conducted between 1966 and June 2020
for studies in patients with suspected stroke; the inclusion and
exclusion criteria are provided below. The PubMed search was
conducted on October 10, 2020, at 12:48:21 P.M.
Eligibility Criteria
The studies that were included met the following criteria: (1)
case–control studies; (2) patients aged ≥18 years; (3) magnetic
resonance imaging or CT performed to confirm the clinical
diagnosis of ischemic stroke; (4) a blood or serum biomarker
assessed within 0–24 h after symptom onset; (5) the study
reported the relationship between biomarker level and diagnostic
accuracy; (6) the study included two or more biomarkers
because the use of a biomarker panel improved the sensitivity
and specificity for identifying cases of stroke in comparison
with a single biomarker (20); and (7) the study reported
the sensitivity, specificity, and AUC for the model for stroke
diagnosis. We selected articles written in English or Spanish.
Reviews, conference abstracts, and editorial letters were excluded.
Mendeley was the reference management software used for the
identification, elimination of duplicates, and screening purposes.
The studies were selected based on the title and abstract for one
author in the first phase (SB). In the second phase, we read the
full text of the preselected articles and included studies matching
the eligibility criteria (Figure 3). Disagreements were resolved
by consensus.
Data Extraction
One of the authors (SB) extracted all the data needed to meet
the review goals, including publication year, first author, sample
size (n), biomarkers used, assays used to measure the biomarker,
biomarker cutoff value used (if available), blood draw time,
and the values of AUC, sensitivity, and specificity. This review
followed the Preferred Reporting Items for Systematic Reviews




A total of 704 articles emerged from the initial search process
as potentially relevant records, and five were added manually
based on the author’s recommendations; 698 studies remained
after the manual removal of duplicates. The screening process
ruled out 645 articles based on abstract and title for the
following reasons: articles related to cardiovascular diseases or
other diseases (pulmonary embolism, Alzheimer disease, renal
disorders, and others); articles evaluating the risk of stroke;
and reviews and meta-analyses involving outcome and mortality
and being related to genetic biomarkers. Finally, 53 full reads
were selected and assessed for eligibility, and 41 were eliminated
because of evaluating individual biomarkers, drawing blood after
24 h, and not reporting AUC, sensitivity, or specificity. Finally, 12
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FIGURE 3 | PRISMA diagram. Flow diagram of the search and screening process. PubMed research yielded 704 articles at baseline, and five were added manually.
No other sources of article identification were identified.
articles were included in the systematic review. A PRISMA flow
diagram describing the search and screening process is shown in
Figure 3.
An example of a systematic review that was not included
in our evaluation because of a lack of statistical measures
of diagnostic accuracy was a recent meta-analysis evaluating
several biomarkers (25). Most of the biomarkers evaluated in
this study are reported in the literature and are reviewed as
potential candidates and are added in several panels below;
however, von Willebrand factor (vWF) and NR2 were omitted.
Note that glial fibrillary acidic protein (GFAP) was the most
promising biomarker in the study of separate ischemic stroke
(IS), intracerebral hemorrhage (ICH), and healthy controls.
The same study mentions D-dimer, matrix metalloproteinase 9
(MMP-9), brain natriuretic peptide (BNP), and protein S100-β
(S100β) derived from the meta-regression analysis as significant
markers to be evaluated within 6 and 24 h of symptom onset (22).
Study Characteristics
The main features of the selected studies are listed in Table 1.
Regarding sample characteristics, all the studies were case–
control, which included control participants (without stroke),
patients with acute IS (AIS), ICH, TIA, mimics, closed-head
injuries (CLHs), or subarachnoid hemorrhage (SAH). All the
studies involved subjects aged ≥18 years, and in the majority,
immunoassays were used to evaluate the levels of biomarkers.
Most of them reported their values of sensitivity, specificity,
or AUC obtained within the first 6 h of symptom onset using
multivariate or univariate regression logistic analyses.
Biomarker Analysis Based on Selected
Studies
One of the biomarker panels frequently evaluated for the
identification of AIS is composed of four proteins: BNP, D-dimer,
S100β, and MMP-9 (23–25). The results of previous studies have
been mixed as follows:
• Laskowitz et al. (23) showed that combining these four
proteins outperformed other biomarkers in differentiating
mimics from intracranial hemorrhage cases, with c = 0.76.
This result was validated in a study of 293 subjects, 361
mimics, and 197 TIA with a validation cohort of 343
suspected stroke cases. The study’s global results to classify
stroke cases exhibited a high sensitivity of ∼90% but a low
specificity of ∼45%, and 91% sensitivity and 45% specificity
for differentiating specific IS.































TABLE 1 | Summary of the 12 articles included in the systematic review.
Biomarker panel Sample size (n)/groups Time Essays Cut off Specificity Sensitivity Area under the
curve
References
BNP, D-dimer, MMP-9, and
S100β
ICH vs. mimics
n = 946 subjects
293 (IS), 95 (ICH), 197 (TIA),
and 361 (mimics)
343 subjects for the
validation cohort: 87 (IS), 64





























n = 139 subjects
89 (AIS), 11 (ICH), and 39
(brain disorders)
AIS vs. others (control,
brain diseases)












n = 174 subjects
100 (IS), 49 (mimics), and
25 (TIA)
IS vs. mimics
<6 h Triage® Stroke
Panel
— 33% 86% 0.59 (25)
Eotaxin, EGFR, S100A12,
TIMP-4, and prolactin
n = 167 subjects
57 (IS), 32 (ICH), 41 (TIA),
and 37 (mimics)
IS + ICH vs. mimics
<24 h — — 84%






n = 1,005 subjects














S100β, MMP-9, VCAM, and
vWF
n = 80 subjects
44 (IS), 21 (controls), 13





Biosite Inc. — 90% 90% — (28)
S100β, BNGF, vWF,
MMP-9, and MCP-1
n = 274 subjects
82 (ISCH), 65 (SAH), 38
(ICH), 38 (closed head
injuries, CLH), and 51 (TIA)









n = 52 subjects
28 (IS) and 24 (No-Stroke)
IS vs. no stroke
<6 h Albumin–cobalt
binding (ACB) test


















































































TABLE 1 | Continued





n = 198 subjects
152 (IS) and 46 (mimics)














Ab NR2 and GFAP n = 124 subjects
49 (IS), 23 (ICH), 52 controls
IS vs. ICH
<12 h GFAP: ELISA kit
AB NR2: Gold Dot
NR2 Antibody
Assay kit (ELISA)
— 91% 94% — (32)
GFAP/UCH-L1
GFAP
n = 184 subjects
45 (ICH), 79 (IS), 5 (SAH), 3











0.71 (IS vs. C)
0.95 (ICH vs. C)





n = 1,308 subjects
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• Kim et al. (24) validated the previous biomarker panel using
the composite multimarker index (MMX), which combines
the individual marker values into a single index value. It
exhibited good performance in the discrimination of patients
with acute infarction; at 6 h, it could differentiate AIS (p <
0.001) but with insufficient precision. With 91.0% sensitivity,
21.3% specificity, and 71.4% AUC, the analysis exhibited a
modest discriminatory power for acute stroke. According to
the MMX values, there was no significant difference between
the subjects with AIS and those with ICH (p= 0.884).
• These promising results should be considered with caution.
Knauer et al. (25) evaluated MMX in a cohort of 174 cases
in which 100 patients had stroke, 49 were mimics, and 25
had TIA. They advised against the use of the panel BNP, D-
dimer, S100β, and MMP-9 in this assay because of (1) the
low significance of MMX values to differentiate the IS group
(MMX = 3.6 ± 2.0) from mimics (MMX = 4.2 ± 1.7) and
(2) the low significance of MMX values when the analysis
for the individual biomarkers was replicated. The 2.3 cutoff
value of MMX was reported to have 86% sensitivity with a low
specificity of∼33% and an AUC of∼59%.
A panel comprising eotaxin, EGFR, S100A12, metalloproteinase
inhibitor-4 (TIMP-4), and prolactin was found to be elevated
in a study of 167 cases with neurologic deficits, allowing the
differentiation of IS cases from mimics (c= 0.92) (26). The study
used a time window of 24 h and reported a high specificity of
∼84%, sensitivity of∼90%, and AUC of∼97%.
Another panel, caspase-3, D-dimer, chimerin-II, MMP-9,
secretagogin, and sRAGE, was assessed in a large cohort of
1,005 cases where 915 had strokes and 90 had stroke-mimicking
conditions, but only proteins could discriminate between the two
groups (27). At 6 h after symptom onset, these protein levels
had moderate sensitivity values of ∼84% but a low specificity
of∼63%.
The panel S100β, MMP-9, vascular cell adhesion molecule
(VCAM), and vWF proved to have good discriminatory power
as it differentiated 44 AIS cases from 21 controls within the
first 6 h after symptom onset with high sensitivity (∼90%) and
specificity (∼90%).
A panel slightly modified from the previous one comprising
S100β, MMP-9, and vWF with two other markers including
monocyte chemoattractant protein-1 (MCP-1) and B-type
neurotrophic growth factor (BNGF) had similar discriminatory
power (29). The levels for the panel in samples of 82 ISCH (IS
with ICH), 65 SAH, 38 ICH, 38 CLH, and 51 TIA patients, at 6 h
from symptom onset and using multivariate logistic regression
model, had elevated sensitivity of ∼92% and specificity of ∼93%
in the classification of ischemic events and a specificity of ∼93%
and sensitivity of∼80% for the prediction of hemorrhagic stroke.
The protein GFAP has been of interest in combination
with other biomarkers. The combination of antibodies (Ab)
against NR2 and GFAP exhibited the best predictive power for
comparing 49 IS subjects from 23 ICH patients and 52 controls. A
sensitivity of∼91% and specificity of∼94% were reported within
12 h of symptom onset (32). The use of GFAP and UCH-L1 for
the identification of ICH vs. IS was tested in 129 stroke subjects,
three TIA patients, and 57 controls (33). Notably, GFAP alone
was capable of distinguishing between the condition with anAUC
∼0.86, sensitivity of 61%, and specificity of 96% (33).
Recently, a panel consisting of apolipoprotein CIII (Apo C-
III), NT-proBNP, and FasL was selected as the best combination
after an extensive study of 21 biomarkers in 1,308 cases to
differentiate real stroke frommimics, within 6 h after stroke onset
(34). This study was replicated with a smaller sample size for
a different group of subjects, giving a modest accuracy of 0.742
(0.686–0.797). Despite being one of the studies that screened the
largest number of biomarkers, this, in our opinion, has some
limitations. GFAP was not assayed, and the levels of MMP-9 were
not measured in the entire cohort because they were not deemed
discriminative (34).
Finally, it is worth mentioning the two articles that screened
several biomarkers, although they did not combine them. They
can be integrated into an optimized panel in the future. The
studies and biomarkers are as follows:
• Ischemia-modified albumin (IMA): in a small number of
patients (n = 28) with stroke compared to the no-stroke
group (n = 24) where the albumin-adjusted IMA index and
IMA were measured within 6 h after symptom onset (30).
Furthermore, the IMA index (98 U/mL) was even more
sensitive (sensitivity, ∼95.8%; specificity, ∼96.4%; and AUC,
∼99%) than the conventional IMA value (sensitivity,∼87.5%;
specificity, 89.3%; and AUC, 92.8%) for the detection of
patients with cerebral ischemia.
• The levels of antithrombin III (AT-III) in a study with 152
stroke patients and 46 mimics reported the highest sensitivity
of∼97.37% and specificity of∼93.62% using a cutoff of 210%,
whereas 4 g/L of fibrinogen reached a sensitivity of ∼96.05%
with a specificity of∼82.61% (31).
Observations From the Selected Studies
(1) Only two biomarkers, NR2 peptide (Ab against NR2
fragment) and GFAP, have been reported as brain-specific
markers linked to the progression of stroke, reaching the
highest predictive power when evaluated together (32).
(2) Two proteins that have been widely used as biomarkers are
vWF and MMP-9; however, they are not specific to stroke.
Although they were evaluated in a combined panel with higher
accuracy (28, 29), Reynolds et al. reported that vWF andMMP-
9 alone could not be used for diagnosis. However, it has good
univariate discrimination of non-diseased vs. diseased, with an
added discriminatory capacity to the logistic regression model
[p < 0.0001; (29)].
(3) S100β is one of the most evaluated biomarkers; however, it
is also not specific to stroke. Along with GFAP, it is one of the
strong candidates for the differentiation of hemorrhagic and
ischemic subtypes in the acute phase of stroke (35).
(4) An IMA index is the IMA value multiplied by individual
serum albumin concentration/median albumin of the study
population (36). The IMA index seems to bemore specific than
IMA in the differentiation of IS, but it has not been used in
combination in previous studies.
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(5) According to previous studies, the use of AT-III and
fibrinogen might help in distinguishing between conditions
with high accuracy in individual analyses (31).
(6) Usually, ROC curves are the statistical method to compare
two groups of patients: ICH vs. mimics, AIS vs. other groups,
IS vs. mimics, and IS+ ICH vs. mimics.
(7) Note that none of these results have been approved for
advanced clinical trials.
PROTEINS DERIVED FROM THE
SYSTEMATIC SEARCH AND THEIR
RELATION TO THE PATHOPHYSIOLOGY
OF STROKE
We have selectively outlined concepts of stroke pathophysiology
that justified our proposals for novel biomarker panels for clinical
prediction explained with graphical details in Figure 4:
(1) When rupture of the endothelial layer of the vessel
occurs, the inner collagen layer is exposed. The exposure
of collagen with blood is recognized by platelets, forming a
sticky plug that initiates clot formation (37). Consequently,
endothelial cells release vWF, MMP-9, P-selectin, E-selectin,
and inflammatory mediators (38). vWF promotes platelet
adhesion to the damaged site by forming a molecular bridge
between the subendothelial collagen matrix and the platelet-
surface receptor complex GPIb-IX-V (39). Fibrinogen is
released from the liver to the bloodstream and is cleaved by
thrombin at the damaged site, resulting in fibrin formation.
Fibrin is one of the main constituents of blood clots and
provides remarkable biochemical and mechanical stability
(40). The conversion of fibrinogen to fibrin by thrombin
is inhibited by the enzyme AT-III, which is downregulated
during an ischemic event. Neutrophils and leukocytes also
adhere to the injury site and form a solid structure that
obstructs or reduces blood (Figure 2).
(2) Flow reduction leads to the depletion of oxygen and
glucose, which has severe implications for cell function,
resulting in dysregulation of neuronal homeostasis. The
process of intracellular medium acidification is reported
when metabolism changes to anaerobic conditions (41).
Mitochondrial dysfunction plays a significant role in inducing
neuronal death caused by an increase in enzymes that favor
the production of reactive oxygen species (ROS) and reactive
nitrogen species (RNS), such as xanthine oxidase, NADPH
oxidases, nitric oxide synthase, and a decrease in detoxifying
systems (42, 43). Note that ROS and RNS pass into the
bloodstream and are hypothesized to modify the N-terminal
of albumin (44).
(3) Mitochondrial dysfunction affects ATP production, which
induces a failure in the activity of the Na+–K+ pump. Na+–K+
pump activity depends on ATP hydrolysis (45), disappearing
the electrical gradient in the cellular membrane and causing
the influx of Na2+ into the neuron, resulting in membrane
depolarization. Simultaneously, the activation of ASC1a, NCX,
and TRP allows the influx of Ca2+ into the neuron, a process
known as calcium overloading (46). Calcium overloading
favors glutamate release into the extracellular medium and
causes swelling due to the influx of water. NR2 is a subunit of
the N-methyl-D-aspartate (NMDA) receptor and is a ligand-
gated ion channel with high calcium permeability, which is
cleaved by serine proteases under ischemic conditions (47).
(4) All these processes lead to neuronal death by necrosis
or necroptosis, characterized by the loss of membrane
integrity, damage to cellular structures, swelling, and release of
cellular content, resulting in an acute inflammatory response
(48). Consequently, there is an activation of astrocytes
and microglia, which induces morphological changes and
mediates the inflammatory response (49–51). These cells
release proteins such as S100β and GFAP, reflecting structural
and functional damage in the central nervous system (CNS)
(35). MMP-9 is released by endothelial cells, astrocytes, and
microglia and is activated by high nitric oxide concentrations.
It degrades type IV collagen present in the endothelial blood–
brain barrier, increasing parenchymal destruction, and is
related to the inflammatory response after stroke (52).
PROPOSAL FOR NEW BIOMARKER
PANELS
Based on our reviewed pathophysiology, we suggest further
studies of three different panels (Table 2). We have included
NR2 peptide and GFAP in all proposed panels because they
seem to be the most promising brain-specific biomarkers
related to stroke. We have included other biomarkers in the
suggested panels under Observations From the Selected Studies
described above because they seem promising in light of the
pathophysiological process of stroke that have been previously
evaluated (Table 3).
Panel 1: NR2+ GFAP+MMP-9+ vWF+ S100β
• NR2: Precisely, the NR2 subunit is the only biomarker
reported with the highest specificity (96%) and sensitivity
(92%) at 12 h using a cutoff value of 1.0 µg/L in 101 IS
and 91 no-stroke patients (60). When a lower cutoff value
of 0.5 ng/mL was tested within 0.5–4.5 h, it revealed high
sensitivity and specificity of 88 and 99%, respectively, for
the differentiation between mild traumatic brain injury, AIS,
ICH, healthy controls, and subjects at risk of TIA (vascular
risk factors) (https://www.ahajournals.org/doi/10.1161/str.44.
suppl_1.A30). Additionally, the concentrations of NR2 were
found to be significantly elevated in IS subjects compared with
patients without cerebral damage and were also related to the
size of infarct and were used as a blood test for the validation
of Cortexin treatment, a neurocytoprotector (61).
• GFAP: The predictive value of GFAP to determine the types
of stroke was assessed by Foerch, who used a cutoff value
of 2.9 ng/L, obtaining a sensitivity of 79% and a specificity
of 98% (53). The same author, after several years, ratified
GFAP as an efficient marker to differentiate ICH from IS,
including stroke mimics [AUC = ∼0.915; 95% confidence
interval (CI) = 0.847–0.982; p < 0.001; (62)]. Recently, the
potential of using a value of 0.43 ng/mL was found, achieving
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FIGURE 4 | Proteins derived from the proposed panel of biomarkers and their relation to the pathophysiology of stroke. After an injury, endothelial cells release
MMP-9, which plays an essential role in the extracellular matrix and local proteolysis of leukocyte migration. In addition, endothelial cells release vWF in a globular
form, which is then transformed into an elongated form by the activity of the ADAMTS13 enzyme. vWF promotes platelet adhesion to the damaged site by forming a
molecular bridge between the subendothelial collagen matrix and the platelet-surface receptor complex GPIb-IX-V. Fibrinogen is released from the liver to the
bloodstream and is cleaved by thrombin at the damaged site, resulting in fibrin formation. Fibrin is one of the main constituents of blood clots and provides remarkable
biochemical and mechanical stability. The conversion of fibrinogen to fibrin by thrombin is inhibited by the enzyme antithrombin (AT-III), which is downregulated during
an ischemic event. In addition, neutrophils and leukocytes arrive at the injured site and join with the previous proteins to form a solid structure that obstructs or reduces
blood flow. These conditions lead to a shift in the neuron’s metabolic conditions, mitochondrial dysfunction, excitotoxicity, and ion imbalance. The reactive oxygen and
nitrogen species released from the mitochondria can pass into the bloodstream and modify the circulating albumin. On the other hand, microglia and astrocytes sense
the conditions and produce S100β and GFAP to signal neuronal damage. In synapsis, because of ion imbalance, the release of the NR2 peptide and glutamate
occurs. The NR2 peptide can be recognized as an antigen in the blood flow and induces an immunological response. Figure was drawn using Biorender.com.
the highest diagnostic accuracy for the differentiation between
ICH and AIS (sensitivity ∼91%, specificity ∼97%) within 6 h
after symptom onset (63). Ren et al. demonstrated that the
median concentration of this protein in patients with IS with
no history of stroke was lower than that in cases with a history
of stroke (0.015 vs. 0.07 ng/mL, respectively, p= 0.004) (33).
• vWF was found to be higher in stroke patients, and it has been
associated with the CE and large-vessel disease (LVD) subtypes
(64). Additionally, its levels have been related to the severity
of arterial thrombus formation and poor functional outcomes
(65, 66). In a proteomics prospective clinical study, vWF could
differentiate TIA and minor stroke from non-cerebrovascular
(mimic) conditions [1.256 (1.034–1.527)] (67). Furthermore,
vWF can be a sign of the response following thrombolytic
therapy or endovascular treatment in IS patients (65, 68).
• MMP-9: Higher concentrations of this protein have been
observed early, in the acute phase, and later in stroke (69).
MMP-9 levels are correlated with infarct volume, neurological
deficits, and infarct progression (70, 71). This could be a
measure of the transformation to hemorrhagic stroke after
thrombolytic treatment (69, 72, 73). MMP-9 levels may be
indicative of an inflammatory response after stroke (55),
endothelial dysfunction (52), and response to thrombolytic
treatment after IS (69, 72, 74). Recently, Misra et al. concluded
that its levels could differentiate between IS, ICH, stroke
mimics, and control subjects (p < 0.05) in a systematic review
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TABLE 2 | Proposal of biomarker panels for stroke recurrence.
Biomarker panel proposal
NR2+ GFAP+ MMP-9 + vWF + S100β
NR2 + GFAP + MMP-9 + vWF +IMA index
NR2+ GFAP+ AT-III + fibrinogen
and meta-analysis of studies realized at 24 h. However, within
6 h, IS could not be differentiated from other groups (ICH,
stroke mimics, and controls) (22).
• S100β is released early into the peripheral blood and is
correlated with the National Institutes of Health Stroke Scale
scores, infarct volume, and severity (29, 75). Foerch et al.
reported that it could be used for <6 h as an indirect time
and for successful clot lysis (75). At days 2 to 4 after acute
stroke, S100β can be predictive of the disease’s course with
higher accuracy, associating the higher levels with the worst
functional status, making its evaluation an effective recurrent
biomarker (76, 77). S100β was able to separate IS from
mimics [standardized mean difference (SMD) = 0.41; 95%
CI = 0.18–0.63] but failed to identify healthy controls, as
well as ICH at 6 h (22). In addition, no significant differences
were reported in an analysis that compared biomarker values
between different conditions (34).
Panel 2: NR2+ GFAP+MMP-9+ vWF+ IMA index
We have decided to eliminate S100β in the second and third
panels because GFAP is a much more brain-specific biomarker
(35). We have added the IMA index in this panel because it has
not been previously assayed.
• IMA index: Several studies have probed the use of IMA as
a diagnostic marker of acute coronary syndrome and AIS
(30, 56, 78). Their admission levels were also associated with
people suffering from acute aortic dissection (79) and can
differentiate between ICH and IS patients (80).
Panel 3: NR2+ GFAP+ AT-III+ fibrinogen
We have decided to eliminate MMP-9 and vWF in
the third panel because AT-III and fibrinogen are also
biomarkers of the coagulation process and reflect the thrombotic
status. Both proteins were individually evaluated in a meta-
analysis, which did not show significant differences (22), but
we recommend their assessment together in a multivariate
regression logistic model.
• Fibrinogen is one of the markers with an essential role
in the thrombosis process because it is related to platelet
aggregation after injury and inflammation (40, 59). In the case
of an ischemic event, an association between elevated levels
of this protein and increased risk has been reported (81, 82).
Fibrinogen has been used to evaluate the long-term outcome
and the size of the clot burden in patients after stroke (83, 84).
• AT-III is involved in the blood coagulation cascade, and
inactive AT-III-thrombin complexes are formed during the
acute phase of stroke (57). Peripheral blood concentrations are




To the best of our knowledge, this is the first systematic and
comprehensive study to summarize current evidence regarding
the use of combinations of biomarkers in the early stages
of stroke. A sobering observation is that, despite numerous
published studies, none of the protein biomarkers reported,
alone or in combination, have been approved for the clinical
management of stroke. It seems that, at best, these biomarkers
can serve as support for clinical and imaging evaluation of
patients. The objective of this study was to facilitate the
identification of stroke mimics and allow dynamic follow-up
of a patient’s state to guide neuroprotective interventions. The
diagnostic accuracy of stroke biomarkers must be accurate and
time-sensitive to allow such dynamic follow-up. A significant
result from our review is that combinations of biomarkers exhibit
higher diagnostic accuracy than isolated biomarkers. Thus, there
seems to be a substantial area for improvement by employing
biomarker panels.
Based on our review, we suggest using three new panels of
protein biomarkers to evaluate the pathophysiology of stroke.We
have noted that the combination of GFAP and NR2 is included
to determine neuronal damage with high accuracy in all three
proposed panels. NR2 peptide is a brain-specific biomarker that
has shown promising results for the distinguishing stroke, with
one of the highest reported accuracies. Therefore, it is surprising
that few studies have used it in combination with other proteins.
The suggestion to include it in all three panels is based merely on
this fact.
An intriguing possibility is that we might be able to monitor
people with hemorrhagic and IS using a combination of S100β,
GFAP, and IMA indices. S100β and GFAP have the same kinetics
during cerebrovascular events. During ICH, both proteins peak
early, before 24 h. The peak was reached later for the ischemic
events. This difference in kinetics suggests that early peaking
of blood levels of S100β and GFAP could be the hallmark of
ICH during the acute phase of stroke (35). This crucial, yet
still unresolved, distinction between IS and ICH is essential to
make a decision about interventions. Likewise, blood proteins
can contribute to treatment optimization for ISs by providing
detailed information about hemostatic conditions involving
pathways of coagulation activation, fibrinolysis, and endothelial
function (85).
Of course, future studies might be based on panels other
than those proposed in this study. Other promising biomarkers,
such as glycogen phosphorylase isoenzyme BB (GPBB) (86),
APOA1-UP (87), and platelet basic protein, have been described
previously (88). These proteins have emerged as possible
candidates showing high accuracy for distinguishing different
conditions; however, more research is required to achieve the
desired results of sensitivity and specificity during the process
of validation.
Limitations of Our Review
There are certain limitations to our study:
1. We only focused on studies conducted on IS caused by small-
vessel disease due to the small number of studies reported
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TABLE 3 | Biomarkers derived from the biomarker panel proposal and their possible role identified in stroke.








2A, and NMDA 2B
It is a ligand-gated ion channel with
high calcium permeability and
voltage-dependent sensitivity to
magnesium. It is essential in the
process of neuronal synapses.
As a response to the brain’s ischemic
conditions, serine proteases are
activated, which causes the cleavage
of the NR2 subunit of NMDA
receptors (NMDARs). Then its subunit
is released to the blood, being a
marker of neuronal damage.
(47)
GFAP GFAP Glial fibrillary acidic
protein
It is an intermediate filament class-III.
It is classified as a glial marker.
After an injury, trauma, disease,
genetic disorders, or chemical insult
GFAP is released from reactive
astrocytes. The process is named
astrogliosis and reflects structural and
functional damage in the CNS.
(51, 53)
S100β S100β Protein S100-β It is a protein-related to calcium
metabolism. Also, it participates in the
transmission of intracellular signals
through second messengers. It is
involved in the development and
maintenance of the CNS. It is
classified as a glial marker.
It is released from astrocytes and
microglia after an injury or trauma,
reflecting the CNS’s structural and
functional damage. It is directly
related to the volume of lesions,
clinical status, and functional
outcome.
(29, 50)
vWF VWF von Willebrand
factor
It plays an essential role in the
maintenance of hemostasis, blood
coagulation, and cell adhesion.
It is secreted by the endothelial cell
activated in response to injury and
can adhere to circulating platelets and





It is a proteolytic enzyme belonging to
the group of gelatinases. It has an
essential role in local proteolysis of
the extracellular matrix and leukocyte
migration.
It is activated by high concentrations
of oxide nitric and degrades the type
IV collagen present in the endothelial
blood–brain barrier, increasing its
parenchymal destruction. It is related
to the inflammatory response after
stroke.
(52, 55)
IMA index (albumin) ALB Albumin It is the major transporter of Zn, Ca2+,
Mg in plasma and binds water Na+,
K+, fatty acids, hormones, etc. It
regulates the colloidal osmotic
pressure of blood.
Under ischemic conditions, it is a
measure of oxidative stress, where
the NH2 terminus of human albumin
may be modified for the free radicals,
but the precise mechanism is yet
unknown.
(30, 44, 56)
AT-III SERPINC1 Antithrombin III It is a plasma serine protease inhibitor
that regulates the blood coagulation
cascade and inhibits the thrombin.
Inactive AT-III–thrombin complexes
are formed during the acute phase of
stroke.
(57, 58)
Fibrinogen FGA, FGB, FGG Fibrinogen It is a blood glycoprotein essential in
coagulation and determines the
plasma viscosity.
It is related to the thrombosis process
favoring the platelet aggregation after
injury, being one of the primary
components of blood clots.
(40, 59)
in the literature regarding the subtype classification of stroke
through biomarker combinations.
2. For the same reason, we evaluated only case–control studies,
although this selection was intentional.
3. We did not carry out meta-analyses because of the high
heterogeneity of the reported data and the wide variety of
proteins used. Future studies must include statistical methods
that ensure sufficient power to detect valid effects.
4. We could not identify a sufficient number of studies on
biomarkers or panel biomarkers in stroke subtypes. Possible
covariables interfering with the specificity of the biomarker
[e.g., age, medications, lifestyle factors, and diseases; (16)]
must also be incorporated into the statistical model.
However, this review highlights additional general
methodological issues when studying stroke biomarker panels.
These, of course, generate open questions that we have briefly
discussed. We also comment on the design issues for testing the
proposed panels.
Considerations on the Statistical Methods
in the Literature
Many studies do not provide complete information on the
accuracy of diagnostic procedures to distinguish between
two patient groups. Most articles report only sensitivity
and specificity, which are threshold-dependent. We only
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TABLE 4 | Summary of the biomarkers for the determination of the subtypes of stroke.
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AUC = 0.91 with Atrial Fibrillation (AF)
AUC = 0.84 without AF
(94)
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Troponin Embolic stroke of unknown
source (ESUS)
ESUS vs. CE, non-CE
1,120 IS [CE = 371,
non-CE = 310, and embolic





95 % 12% (97)
Troponin Cardioembolic
CE vs. ESUS, non-CE
1,120 IS [CE = 371,
non-CE = 310, and embolic





95 % 17% (97)
(Continued)
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TABLE 4 | Continued




SVD vs. CE + LVD
126 patients (LVD = 34,CE = 34,











197 acute lacunar infarction











197 acute lacunar infarction











197 acute lacunar infarction













LVD vs. other strokes
128 patients (LVD = 23,
non-LVD = 42, HS = 16, stroke









Bold values indicate groups compared in the studies analyzed by Receiver Operating Curve analysis (ROC).
included those providing the AUC in our review (89). See
Supplementary Table 4 for the comparison. However, even
this reporting level is insufficient because it is only useful to
distinguish between the two groups. Critical clinical questions
are therefore left unanswered when they require a distinction
between several patient categories. To answer such questions
involving three or more diagnostic groups, more sophisticated
techniques are needed. Examples include the Youden index test
proposed to generalize ROC curves by Obuchowski et al. (89) and
Luo and Xiong (90).
Unanswered Clinical Questions
• Are biomarker panels useful for stratifying stroke risk
levels? For example, this question was examined by Laskowitz
et al., who classified patients who applied logistic regression
to a combination of biomarkers. These results showed that
the odds ratio might be a good predictor of stroke risk. A
similar evaluation was included in the evaluation protocol of
the biomarker panels.
• Are biomarker panels able to discriminate between small
and large vessel strokes? This question is crucial because these
conditions require entirely different therapeutic or vascular
surgical treatment approaches. Significantly, the accuracy
of a biomarker panel might depend on this etiological
difference. Unfortunately, few studies have addressed this
issue quantitatively. In Table 4, we report the results of
protein biomarkers with differential sensitivity to small-vessel
disease and LVD. Note that our proposed panels include
several biomarkers (as detailed in Supplementary Table 1),
thus having the potential for this distinction.
• Are biomarker panels able to discriminate CE and LVD
stroke etiology? Note that the accuracy of a biomarker panel
might depend on the etiology of the IS. However, only a
few studies have considered this issue (Table 4). The selected
proteins for our proposed panels could have great potential
because of their differential expression of serum levels in these
stroke subtypes (Supplementary Table 3).
• Are biomarker panels useful for the follow-up of
mixed stroke cases? Here, we refer to both hemorrhagic
transformations of IS and secondary ischemic injury after
ICH. Indeed, specific proteins have been explored in this
context, as shown in Supplementary Table 2. These proteins
have been included in our proposed panels, and studies to
evaluate them will consider this aspect.
We hope that this review will stimulate additional proposals of
other biomarker panels that might contribute to the long-term
objective of stroke precision medicine. We emphasize again that
we have concentrated on biomarkers obtainable from plasma at
a low cost with scalable technologies in any economic setting. If
not these panels of biomarkers for stroke, then similar ones might
be the key to tackling the global burden of disease due to stroke.
CONCLUSIONS
More research is needed to validate, identify, and introduce
into medical practice useful biomarkers for stroke recurrence
or diagnosis in a scalable manner. The most promising
approach is to combine a panel of different blood-
based proteins to provide acceptable diagnostic precision
for health interventions. After a systematic review, we
suggest three novel biomarker panels based on the
results in the literature with an interpretation based on
stroke pathophysiology.
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